Biblio

Author Title [ Type(Asc)] Year
Filters: Author is Hashmi, Shahrukh  [Clear All Filters]
Journal Article
Hashmi S, Shaheen M, Adil S, Ahmed P, Ahmed S, Ben Abdeljelil N, Alabdulwahab A, Albeihany A, Aldaama S, Al-Khabori M, et al. Unique aspects of Graft-versus-host-disease management in the Eastern Mediterranean region: Report from the Eastern Mediterranean blood and marrow transplantation group: Special report. Hematol Oncol Stem Cell Ther. 2023;16(4):303-306.
Hashmi S, Shaheen M, Adil S, Ahmed P, Ahmed S, Abdeljelil B, Alabdulwahab A, Albeihany A, Aldaama S, Al-Khabori M, et al. Unique aspects of Graft-versus-host-disease management in the Eastern Mediterranean region: Report from the Eastern Mediterranean blood and marrow transplantation group: Special report. Hematol Oncol Stem Cell Ther. 2020.
Sidana S, Kumar S, Fraser R, Estrada-Merly N, Giralt S, Agrawal V, Anderson LD, Aljurf M, Banerjee R, Bashey A, et al. Title: Impact of Induction Therapy with VRD vs. VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. Transplant Cell Ther. 2021.
Hashmi S, Ahmed M, M Murad H, Litzow MR, Adams RH, Ball LM, Prasad VK, Kebriaei P, Ringdén O. Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis. Lancet Haematol. 2016;3(1):e45-e52.
Scott EC, Hari P, Kumar S, Fraser R, Davila O, Shah N, Gale RPeter, Díaz MÁngel, Agrawal V, Cornell RF, et al. Staging Systems for Newly Diagnosed Myeloma Patients undergoing Autologous Hematopoietic Cell Transplant: The Revised International Staging System shows the most Differentiation between Groups. Biol Blood Marrow Transplant. 2018.
AlMozain N, Mashi A, Alnaemi Q, Al-Omran A, Bakshi N, Owaidah T, Khalil S, Khogeer H, Hashmi S, Al-Sweedan S, et al. Spectrum of myelodysplastic syndrome in patients evaluated for cytopenia(s). Hematol Oncol Stem Cell Ther. 2020.
Tamari R, McLornan DP, Ahn KWoo, Estrada-Merly N, Hernández-Boluda JCarlos, Giralt SA, Palmer JM, Gale RPeter, DeFilipp Z, Marks D, et al. A Simple Prognostic System in Myelofibrosis Patients Undergoing Allogeneic Stem Cell Transplant: A CIBMTR/EBMT analysis. Blood Adv. 2023.
Li Z, Mewawalla P, Stratton P, Yong ASM, Shaw BE, Hashmi S, Jagasia M, Mohty M, Majhail NS, Savani BN, et al. Sexual health in hematopoietic stem cell transplant recipients. Cancer. 2015.
Lee CJ, Wang T, Chen K, Arora M, Brazauskas R, Spellman SR, Kitko C, MacMillan ML, Pidala JA, Badawy SM, et al. Severity of Chronic Graft-versus-Host Disease and Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancy. Transplant Cell Ther. 2023.
Zhou Z, Nath R, Cerny J, Wang H-L, Zhang M-J, Abdel-Azim H, Agrawal V, Ahmed G, A Al-Homsi S, Aljurf M, et al. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Adv. 2020;4(13):3180-3190.
Buchbinder D, Brazauskas R, Bo-Subait K, Ballen K, Parsons S, John T, Hahn T, Sharma A, Steinberg A, D'Souza A, et al. Predictors of lost to follow-up among pediatric and adult hematopoietic cell transplant survivors: A report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2019.
Nazha A, Hu Z-H, Wang T, R Lindsley C, Abdel-Azim H, Aljurf M, Bacher U, Bashey A, Cahn J-Y, Cerny J, et al. A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Myelodysplastic Syndromes Patients. Biol Blood Marrow Transplant. 2020.
Murthy HS, Ahn KWoo, Estrada-Merly N, Alkhateeb HB, Bal S, Kharfan-Dabaja MA, Dholaria B, Foss F, Gowda L, Jagadeesh D, et al. Outcomes of Allogeneic Hematopoietic Cell Transplantation in T-cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. Transplant Cell Ther. 2022.
Ragon BKnick, Shah MVinod, D'Souza A, Estrada-Merly N, Gowda L, George G, DeLima M, Hashmi S, Kharfan-Dabaja MA, Majhail NS, et al. Impact of Second Primary Malignancy Post-Autologous Transplantation on Outcomes of Multiple Myeloma: A CIBMTR Analysis. Blood Adv. 2023.
Arnold SD, Brazauskas R, He N, Li Y, Hall M, Atsuta Y, Dalal J, Hahn T, Khera N, Bonfim C, et al. The impact of donor type on outcomes and cost of allogeneic hematopoietic cell transplant for pediatric leukemia: a merged CIBMTR and PHIS analysis: Pediatric acute leukemia transplant risks and utilization. Biol Blood Marrow Transplant. 2020.
Abid MBilal, Estrada-Merly N, Zhang M-J, Chen K, Allan D, Bredeson C, Sabloff M, Murthy GSubramania, Badar T, Hashmi S, et al. Impact of Donor Age on Allogeneic Hematopoietic Cell Transplantation Outcomes in Older Adults with Acute Myeloid Leukemia. Transplant Cell Ther. 2023.
Damlaj M, Sulai NH, Oliveira JL, Ketterling RP, Hashmi S, Witzig T, Nowakowski G, Call TG, Shanafelt TD, Ding W, et al. Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience. Clin Lymphoma Myeloma Leuk. 2015.
Oran B, Ahn KWoo, Fretham C, Beitinjaneh A, Bashey A, Pawarode A, Wirk B, Scott BL, Savani BN, Bredeson C, et al. Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improves Transplant Outcomes in Older MDS Patients. Transplant Cell Ther. 2021.
Ahmed N, Kumar A, Kharfan-Dabaja MA, DeFilipp Z, Herrera A, Hashmi S, Dholaria B, Perales M-A, Carpenter PA, Hamadani M. ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Diffuse Large B-cell Lymphoma after failure of Chimeric antigen receptor T cell therapy (CAR-T) therapy. Transplant Cell Ther. 2022.
Lee CJ, Wang T, Chen K, Arora M, Brazauskas R, Spellman SR, Kitko C, MacMillan ML, Pidala JA, Auletta JJ, et al. Association of Chronic Graft-versus-Host Disease with Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy. Transplant Cell Ther. 2022.
Metheny L, Callander NS, Hall AC, Zhang M-J, Bo-Subait K, Wang H-L, Agrawal V, A Al-Homsi S, Assal A, Bacher U, et al. Allogeneic Transplantation to Treat Therapy Related MDS and AML in Adults. Transplant Cell Ther. 2021.